{"id":"peg-t-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL405705","moleculeType":"Small molecule","molecularWeight":"1256.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Thymosin alpha 1 (Tα1) is an immunomodulatory peptide that stimulates the maturation and differentiation of T lymphocytes, particularly CD4+ and CD8+ T cells. Pegylation extends the half-life and improves pharmacokinetic properties. The drug enhances both cellular and humoral immune responses, making it useful in conditions requiring immune reconstitution or augmentation.","oneSentence":"PEG-Tα1 is a pegylated thymosin alpha 1 that enhances immune function by promoting T-cell maturation and activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:26:04.585Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B"},{"name":"Chronic hepatitis C"},{"name":"Immunodeficiency states"}]},"trialDetails":[{"nctId":"NCT02366208","phase":"PHASE2","title":"Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2011-05","conditions":"Hepatitis B, Chronic","enrollment":116},{"nctId":"NCT02366247","phase":"PHASE3","title":"Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2013-08","conditions":"Hepatitis B, Chronic","enrollment":463}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Polyethylene Glycol thymosin alpha1","Polyethylene Glycol Thymosin alpha1"],"phase":"phase_3","status":"active","brandName":"PEG-Tα1","genericName":"PEG-Tα1","companyName":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","companyId":"jiangsu-hansoh-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PEG-Tα1 is a pegylated thymosin alpha 1 that enhances immune function by promoting T-cell maturation and activation. Used for Chronic hepatitis B, Chronic hepatitis C, Immunodeficiency states.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}